FrancophonIA/ELRC3.0 huggingface dataset:
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 15 mg of aripiprazole.
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 15 mg aripiprasooli.
English: NAME OF THE MEDICINAL PRODUCT Aripiprazole Accord 30 mg tablets aripiprazole
Estonian: RAVIMPREPARAADI NIMETUS Aripiprazole Accord 30 mg tabletid aripiprasool
English: Aripiprazole Accord 15 mg tablets: each tablet contains 15 mg of aripiprazole.
Estonian: Aripiprazole Accord 15 mg tabletid: iga tablett sisaldab 15 mg aripiprasooli.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 10 mg of aripiprazole.
Estonian: TOIMEAINE(TE) SISALDUS Üks tablett sisaldab 10 mg aripiprasooli.
English: Blue colored, approximately 8.1 mm in length, 4.6 mm in width, modified rectangle shaped, biconvex, uncoated tablets, debossed with “A5” on one side and another side is plain.
Estonian: Sinist värvi, ligikaudu 8,1 mm pikkused, 4,6 mm laiused, ristkülikukujulised, kaksikkumerad katmata tabletid, mille ühel küljel on märgistus „A5” ja teine külg on sile.
English: Each 5 mg tablet contains 63 mg lactose (as monohydrate).
Estonian: Teadaolevat toimet omav(ad) abiaine(d) Iga 5 mg tablett sisaldab 63 mg laktoosi (monohüdraadina).
English: Pink colored, approximately 8.1 mm in length, 4.6 mm in width, modified rectangle shaped, biconvex, uncoated tablets, debossed with “A10” on one side and another side is plain.
Estonian: Roosat värvi, ligikaudu 8,1 mm pikkused, 4,6 mm laiused, ristkülikukujulised, kaksikkumerad katmata tabletid, mille ühel küljel on märgistus „A10” ja teine külg on sile .
English: • decreased number of or difficulty making bowel movements,
Estonian: • kõht käib harvem läbi või on sellega raskusi,
English: NAME OF THE MEDICINAL PRODUCT Aripiprazole Accord 5 mg tablets aripiprazole
Estonian: RAVIMPREPARAADI NIMETUS Aripiprazole Accord 5 mg tabletid aripiprasool
English: NAME OF THE MEDICINAL PRODUCT Aripiprazole Accord 10 mg tablets aripiprazole
Estonian: RAVIMPREPARAADI NIMETUS Aripiprazole Accord 10 mg tabletid aripiprasool
English: NAME OF THE MEDICINAL PRODUCT Aripiprazole Accord 15 mg tablets aripiprazole
Estonian: RAVIMPREPARAADI NIMETUS Aripiprazole Accord 15 mg tabletid aripiprasool
English: Reproductive system and breast disorders
Estonian: Teadmata süsteemi ja rinnanäärme häired Üldised häired ja manustamiskoha reaktsioonid
English: EU/1/15/1045/001 14x1 tablets EU/1/15/1045/002 28x1 tablets EU/1/15/1045/023 49x1 tablets EU/1/15/1045/003 56x1 tablets EU/1/15/1045/004 98x1 tablets
Estonian: EU/1/15/1045/001 14x1 tablett EU/1/15/1045/002 28x1 tablett EU/1/15/1045/023 49x1 tablett EU/1/15/1045/003 56x1 tablett EU/1/15/1045/004 98x1 tablett
English: EU/1/15/1045/019 14x1 tablets EU/1/15/1045/020 28x1 tablets EU/1/15/1045/026 49x1 tablets EU/1/15/1045/021 56x1 tablets EU/1/15/1045/022 98x1 tablets
Estonian: EU/1/15/1045/019 14x1 tablett EU/1/15/1045/020 28x1 tablett EU/1/15/1045/026 49x1 tablett EU/1/15/1045/021 56x1 tablett EU/1/15/1045/022 98x1 tablett
English: EU/1/15/1045/013 14x1 tablets EU/1/15/1045/014 28x1 tablets EU/1/15/1045/025 49x1 tablets EU/1/15/1045/015 56x1 tablets EU/1/15/1045/016 98x1 tablets
Estonian: EU/1/15/1045/013 14x1 tablett EU/1/15/1045/014 28x1 tablett EU/1/15/1045/025 49x1 tablett EU/1/15/1045/015 56x1 tablett EU/1/15/1045/016 98x1 tablett
English: To allow the start of the treatment at a low dose you can use an alternative formulation (oral solutionliquid) more suitable than Aripiprazole Accord.The dose may be gradually increased to the recommended dose for adolescents of 10 mg once a day.
Estonian: Selleks, et alustada ravi madalama annusega võib kasutada alternatiivset formulatsiooni (suukaudne lahus, vedelik).
English: EU/1/15/1045/007 14x1 tablets EU/1/15/1045/008 28x1 tablets EU/1/15/1045/024 49x1 tablets EU/1/15/1045/009 56x1 tablets EU/1/15/1045/010 98x1 tablets
Estonian: EU/1/15/1045/007 14x1 tablett EU/1/15/1045/008 28x1 tablett EU/1/15/1045/024 49x1 tablett EU/1/15/1045/009 56x1 tablett EU/1/15/1045/010 98x1 tablett
English: INFORMATION IN BRAILLE Aripiprazole Accord 15 mg 17.
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Aripiprazole Accord 15 mg
English: EMEA/H/C/000169/WS/132/G
Estonian: EMEA/H/C/000169/WS/132/G EMEA/H/C/000255/WS/132/G
English: a clinical trial and need more information about your treatment, contact the doctor who is
Estonian: Kui osalete ravimi kliinilises uuringus ja vajate oma ravi kohta lisateavet, pöörduge palun arsti poole, kes teile ravi määras.
English: The full European Public Assessment Report for Prometax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Prometaxi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Exelon and Prometax are medicines containing the active substance rivastigmine.
Estonian: Exelon ja Prometax on ravimid, mis sisaldavad toimeainena rivastigmiini.
English: The full European Public Assessment Report for Exelon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports
Estonian: Euroopa avaliku hindamisaruande täistekst Exeloni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: s of the medicine can be entia, a progressive lly affects memory, intellectual ability and behaviour.
Estonian: See on progresseeruv ajuhäire, mis kahjustab järk-järgult mälu, vaimseid võimeid ja käitumist.
English: About half of the patients took the capsule, and half were tre for 76 weeks.
Estonian: Umbes pool uuringus osalejatest kasutas 76 nädala vältel kapsleid ja pool transdermaalseid plaastreid.
English: es this withdrawal have for patients in clinical trials?
Estonian: Kuidas mõjutab tagasivõtmine praegu kliinilistes uuringutes osalevaid patsiente?
English: What are Exelon and Prometax?
Estonian: Mis on Exelon ja Prometax?
English: What was the recommendation of the CHMP at that tim
Estonian: Milline oli sel ajal inimravimite komitee soovitus?
English: The Committee therefore considered that the pharmacokinetic data were not sufficient to draw conclusions on the effectiveness of the patch and that additional data would be required.
Estonian: Sel põhjusel leidis inimravimite komitee, et farmakokineetilised andmed on plaastrite efektiivsuse üle otsustamiseks ebapiisavad ja vaja on täiendavaid andmeid.
English: uated the er the CHMP had o the questions, there were still some unresolved issues.
Estonian: Inimravimite komitee oli ettevõttele esitatud küsimuste vastused läbi vaadanud, kuid mõni küsimus oli veel lahendamata.
English: This means that the CHMP had eval documentation provided by the company and formulated lists of questions.
Estonian: Inimravimite komitee oli hinnanud ettevõtte esitatud dokumente ja koostanud ettevõttele vastamiseks küsimused.
English: The company presented the results of a study designed to assess the long-t and transdermal patch in 583 patients with mild to moderately severe dementia ass Parkinson's disease.
Estonian: Ettevõte esitas uuringu tulemused, mille eesmärgiks oli hinnata kapslite ja transdermaalsete plaastrite pikaajalist toimet 583 patsiendil, kellel oli Parkinsoni tõvega kaasnev kerge kuni mõõdukalt raske dementsus.
English: The company had presented pharmacokinetic data showing that, when using the patch, rivastigmine levels in patients with Parkinson's disease were similar to the levels seen in patients with Alzheimer's, but the CHMP noted that the dementia in the two diseases was different and could respond differently to treatment.
Estonian: Ettevõtte esitatud farmakokineetilised andmed näitasid, et plaastri kasutamisel oli rivastigmiini sisaldus Parkinsoni tõvega patsientidel sarnane Alzheimeri dementsusega patsientidel täheldatuga, aga inimravimite komitee pidas vajalikuks märkida, et dementsus on nende kahe haiguse korral erinev ning seetõttu võib erineda ka ravivastus.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of Exelon/Prometax transdermal patch in the treatment of mild to moderately severe dementia associated with Parkinson's disease were uncertain and did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa muutmistaotluse tagasivõtmise ajal arvamusel, et Exeloni/Prometaxi transdermaalsete plaastrite kasulikkus Parkinsoni tõvega kaasneva kerge kuni mõõdukalt raske dementsuse ravis on ebaselge ega ületa kaasnevad riske.
English: y informed the CHMP that there are no consequences for patients currently included in clinical trials with Exelon or Prometax.
Estonian: Ettevõtte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Exeloni/Prometaxi kliinilistes uuringutes osalevaid patsiente.
English: The transdermal patches are expected to work in the same way as the capsules patients with dementia associated with Parkinson's disease, certain nerve cells die i resulting in low levels of the neurotransmitter acetylcholine (a substance that allo communicate with each other).
Estonian: Parkinsoni tõvega kaasneva dementsusega patsientidel hävivad ajus teatud närvirakud, mille tulemusena väheneb neurotransmitteri (keemiline aine, mis vahendab närvirakkude vahelisi signaale) atsetüülkoliini sisaldus.
English: EMEA/H/C/000255/W
Estonian: EMA/226251/2012
English: The capsules and oral solution can also be used to treat mild to moderately severe dementia in patients with Parkinson's disease.
Estonian: Kapsleid ja suukaudset lahust kasutatakse kerge kuni mõõdukalt raske dementsuse raviks ka Parkinsoni tõvega patsientidel.
English: choline to be increased in the brain, helping to reduce the symptoms of dementia in patients with Parkinson's disease.
Estonian: Nende ensüümide blokeerimisega suurendab rivastigmiin atsetüülkoliini sisaldust ajus, mis aitab vähendada Parkinsoni tõvega kaasnevaid dementsuse sümptomeid.
English: capsules, an oral solution and transdermal patches (patches tha Exelon and Prometax have been authorised in the EU since May 1998.
Estonian: Exelon ja Prometax said Euroopa Liidus müügiloa mais 1998.
English: The Committee was concerned that the new study was not sufficient to conclude on of the patch in patients with dementia associated with Pa e the reasons given by the company for withdrawing the d that it decided to withdraw the application after the CHMP de on a favourable approval additional data was required, which could not be generated within the allowed timeframe.
Estonian: Ettevõte märkis oma ametlikus kirjas, et otsustas võtta taotluse tagasi pärast seda, kui inimravimite komitee järeldas, et positiivse otsuse tegemiseks on vaja täiendavad andmeid, mida ei ole ettenähtud ajaperioodi jooksul võimalik saada.
English: Based on the review of the data and the company's response to the CHMP lists time of the withdrawal, the CHMP had some concerns and was of the provisional o transdermal patch could not have been approved for the treatment of mild to
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ning oli esialgsel seisukohal, et transdermaalsete plaastrite kasutamist Parkinsoni tõvega kaasneva kerge kuni mõõdukalt raske dementsuse raviks ei ole võimalik heaks kiita.
English: The active substance in Exelon and Prometax, ri blocking the enzymes that break down acetylcholine: acetylcholin By blocking these enzymes, rivastigmine allows levels of acetyl
Estonian: Exeloni ja Prometaxi toimeaine rivastigmiini toime seisneb atsetüülkoliini lagundavate ensüümide atsetüülkoliinesteraasi ja butürüülkoliinesteraasi blokeerimises.
English: How are Exelon and Prometax expected to work?
Estonian: Milline on Exeloni ja Prometaxi eeldatav toime?
English: What wer application?
Estonian: Mis põhjustel võttis ettevõte taotluse tagasi?
English: On 14 March 2012, Novartis Europ and Prometax, to add the use of the transdermal patch for the treatment of mild to dementia in patients with Parkinson's disease.
Estonian: 14. märtsil 2012 teatas Novartis Europharm Ltd. ametlikult inimravimite komiteele oma otsusest võtta tagasi ravimite Exelon ja Prometax näidustuste laiendamise taotlused.
English: erm effects of the capsule ociated with ated with the patch, he capsules, but the company later extended its aim to include the assessment of the benefits and risks of the ase.
Estonian: Uuring oli esialgu kavandatud kapslite pikaajalise ohutuse hindamiseks, aga hiljem laiendas ettevõte uuringut, lisades selle eesmärkide hulka transdermaalse plaastri kasulikkuse ja riski hindamise Parkinsoni tõvega kaasneva dementsuse ravis.
English: How far into the evaluation was the applicatio
Estonian: Mis järgus oli müügiloa taotluse hindamine, kui see tagasi võeti?
English: All form used for the treatment of patients with mild to moderately severe Alzheimer's dem brain disorder that gradua
Estonian: Kõiki eelnimetatud ravimvorme kasutatakse kerge kuni mõõdukalt raske Alzheimeri dementsuse raviks.
English: This study was originally designed to assess the long-term safety of t transdermal patch in the treatment of dementia associated with Parkinson's dise when given to patients with dementia associated with Parkinson's disease, compared wi in patients with Alzheimer's dementia.
Estonian: Peale selle esitas ettevõte farmakokineetilise analüüsi, mis käsitles transdermaalse plaastri kaudu manustatud rivastigmiini metaboliseerumist organismis, kui seda kasutatakse Parkinsoni tõvega kaasneva dementsusega patsientidel; rivastigmiini metaboliseerumist võrreldi Alzheimeri dementsusega patsientide kohta kogutud andmetega.
English: The transdermal patches of Exelon and Prometax were also expected to be used to treat mild to moderately severe dementia associated with Parkinson's disease, which can already be treated using the capsules and oral solution.
Estonian: Exeloni ja Prometaxi transdermaalseid plaastreid kavatseti kasutada kerge kuni mõõdukalt raske dementsuse raviks Parkinsoni tõvega patsientidel.
English: What is happening with Exelon and Prometax in their authorised ised indications.
Estonian: Kuidas mõjutab müügiloa taotluse tagasivõtmine Exeloni ja Prometaxi kasutamist heakskiidetud näidustustel?
English: What were Exelon and Prometax expected to be used for?
Estonian: Milleks kavatseti Exeloni ja Prometaxi kasutada?
English: Withdrawal of the application for a change to the marketing authorisation for Exelon and Prometax harm Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for an extension of indication for Exelon moderately severe
Estonian: Müügiloa muutmistaotluse tagasivõtmise teave Exelon ja Prometax (rivastigmiin)
English: They are available as t deliver the medicine across the skin).
Estonian: Ravimeid turustatakse kapslite, suukaudse lahuse ja transdermaalsete plaastritena (plaaster, millest ravim imbub organismi läbi naha).
English: There are no consequences on the use of Exelon and Prometax in their author
Estonian: Müügiloa laiendamise taotluse tagasivõtmine ei mõjuta Exeloni ja Prometaxi kasutamist heakskiidetud näidustustel.
English: Adopted at the 3-6 July 2017 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 3.-6. juuli 2017 koosolekul
English: When renal crisis is suspected, blood pressure should be carefully controlled.
Estonian: Renaalse kriisi kahtluse korral tuleb hoolikalt kontrollida vererõhku.
English: Adverse reaction (MedDRA term)
Estonian: Kõrvaltoime (MedDRA termin)
English: • Anaphylactic reactions
Estonian: • Anafülaktilised reaktsioonid
English: For all epoetins - 4.4.
Estonian: Kõik epoetiinid - 4.4.
English: Unless compatibility with other solutions/drugs has been confirmed, the infusion solution must always be administered separately.
Estonian: Seni, kuni ei ole tõendatud sobivus teiste lahuste/ravimitega, peab seda infusioonilahust alati manustama eraldi.
English: The wording below should be adapted at an individual product level and therefore, the type of variation to be submitted should be agreed with the relevant National Competent Authority (NCA) prior to the submission.
Estonian: Allpool esitatud sõnastust peab kohandama lähtuvalt konkreetsest ravimpreparaadist ja seega peab esitatava muudatuse tüübi enne esitamist kooskõlastama asjakohase riikliku pädeva asutusega.
English: Glucose intravenous infusions are usually isotonic solutions.
Estonian: Glükoosi intravenoossed infusioonilahused on tavaliselt isotoonilised.
English: Section Warnings and precautions - Take special care with <product name>:
Estonian: Lõik „Hoiatused ja ettevaatusabinõud“ - „Eriline ettevaatus on vajalik ravimiga <ravimi nimetus>“
English: The doctor may advise that you have your blood pressure and urine regularly checked.
Estonian: Arst võib soovitada teile vererõhu ja uriini regulaarset kontrolli.
English: Blood pressure and renal function (s-creatinine) should therefore be routinely checked.
Estonian: Seega peab regulaarselt kontrollima vererõhku ja neerufunktsiooni (seerumi kreatiniinisisaldust).
English: These may be associated with fever, headaches and body aches
Estonian: Nendega võivad kaasneda palavik, peavalu ja üldised valud
English: For topical formulations, no action is required.
Estonian: Paiksete ravimvormide korral ei ole muudatuste tegemine vajalik.
English: The lowest risk has been reported in patients with limited systemic sclerosis (2%) and juvenile onset systemic sclerosis (1%)
Estonian: Väikseimast riskist on teatatud piiratud süsteemse skleroosi (2%) ja juveniilse algusega süsteemse skleroosiga (1%) patsientidel.
English: The highest risk has been reported in patients with diffuse systemic sclerosis.
Estonian: Suurimast riskist on teatatud difuusse süsteemse skleroosiga patsientidel.
English: If signs and symptoms suggestive of these reactions appear, <product name> should be withdrawn immediately and an alternative treatment considered.
Estonian: Kui ilmnevad nendele reaktsioonidele viitavad tunnused ja sümptomid, peab <ravimi nimetus omastavas käändes> kasutamise kohe lõpetama ja kaaluma alternatiivse ravimi kasutamist.
English: Frequency ‘unknown': Scleroderma renal crisis* *see section c)
Estonian: Esinemissagedus „teadmata”: Süsteemse skleroosi renaalne kriis* *vt lõik c)
English: Fulvestrant - Anaphylactic reaction (EPITT no 18832)
Estonian: Fulvestrant - anafülaktiline reaktsioon (EPITT nr 18832)
English: For all epoetins
Estonian: Kõik epoetiinid
English: Scleroderma renal crisis
Estonian: Süsteemse skleroosi renaalne kriis
English: Frequency not known
Estonian: Esinemissagedus „teadmata“
English: Medicinal products concerned: systemic formulations of prednisolone-containing medicinal products and prednisone-containing medicinal products in doses which provide a systemic concentration equivalent to more than 15 mg prednisolone daily
Estonian: Asjaomased ravimpreparaadid: prednisolooni ja prednisooni sisaldavate ravimpreparaatide süsteemsed ravimvormid annustes, mis tagavad süsteemse kontsentratsiooni, mis vastab 15 mg-le või rohkem prednisoloonile ööpäevas.
English: If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of <product name>, treatment with <product name> must not be restarted in this patient at any time.
Estonian: Kui patsiendil on <ravimi nimetus omastavas käändes> kasutamise tõttu tekkinud raske nahareaktsioon, nagu SJS või TEN, ei tohi ravi <ravimi nimetus kaasaütlevas käändes> sellel patsiendil mitte kunagi uuesti alustada.
English: • Allergic (hypersensitivity) reactions, including swelling of the face, lips, tongue and/or throat that may be signs of anaphylactic reactions
Estonian: • allergilised (ülitundlikkuse) reaktsioonid, sealhulgas näo-, huulte-, keele- ja/või kõripiirkonna turse, mis võivad olla anafülaktilise reaktsiooni tunnused
English: Other medicinal products increasing the risk of hyponatraemia also include diuretics in general and antiepileptics such as oxcarbazepine.
Estonian: Hüponatreemia riski suurendavate muude ravimite hulka kuuluvad diureetikumid üldisemalt ja antiepileptilised ravimid, nagu okskarbasepiin.
English: Intravenous (IV) fluids containing electrolytes and/or carbohydrates - Hyponatraemia (EPITT no 18631)
Estonian: Elektrolüüte ja/või süsivesikuid sisaldavad intravenoossed vedelikud - hüponatreemia (EPITT nr 18631)
English: Comment under the table: *see section “Description of selected adverse reactions” below and sec tion
Estonian: Kommentaar tabeli all: *vt allpool lõik „Valitud kõrvaltoimete kirjeldus“ ja lõik 4.4.
English: Signs of scleroderma renal crisis include increased blood pressure and decreased urine production.
Estonian: Süsteemse skleroosi renaalse kriisi tunnuste hulka kuuluvad vererõhu tõus ja erituva uriinihulga vähenemine.
English: Scleroderma renal crisis in patients already suffering from scleroderma (an autoimmune disorder).
Estonian: Süsteemse skleroosi renaalne kriis juba teadaoleva süsteemse skleroosiga (teatud autoimmuunne haigus) patsientidel.
English: Skin and subcutaneous tissue disorders - (frequency not known) - SJS/TEN, erythema multiforme, blistering, skin ex foliation*
Estonian: Naha ja nahaaluskoe kahjustused - (esinemissagedus „teadmata“) - SJS/TEN, multiformne erüteem, villid, naha eksfoliatsioon*
English: Depending on the tonicity of the solution, the volume and rate of infusion and depending on a patient's underlying clinical condition and capability to metabolize glucose, intravenous administration of glucose can cause electrolyte disturbances most importantly hypo- or hyperosmotic hyponatraemia.
Estonian: Sõltuvalt lahuse toonilisusest, infusioonimahust ja -kiirusest ning patsiendi kliinilisest seisundist ja glükoosi metaboliseerimise võimest võib glükoosi intravenoosne manustamine põhjustada elektrolüütide häireid, millest kõige olulisemad on hüpo- või hüperosmootne hüponatreemia.
English: Undesirable effects Tabulated list of adverse reactions System Organ Class
Estonian: Kõrvaltoimed Kõrvaltoimete tabel Organsüsteemi klass
English: Hyponatraemia:
Estonian: Hüponatreemia:
English: Monitoring of serum sodium is particularly important for hypotonic fluids.
Estonian: Seerumi naatriumisisalduse jälgimine on eriti oluline hüpotooniliste vedelike kasutamisel.
English: • Vasopressin analogues include: Desmopressin, oxytocin, vasopressin, terlipressin
Estonian: • Vasopressiini analoogide hulka kuuluvad: desmopressiin, oksütotsiin, vasopressiin, terlipressiin.
English: Frequency ‘Not known': Drug reaction with eosinophilia and systemic symptoms (DRESS)
Estonian: Esinemissagedus „teadmata“: eosinofiilia ja süsteemsete sümptomitega ravimireaktsioon (DRESS)
English: Amongst the different subpopulations the occurrence of scleroderma renal crisis varies.
Estonian: Süsteemse skleroosi renaalse kriisi esinemissagedus on haiguse erinevates alapopulatsioonides varieeruv.
English: Ciprofloxacin; meropenem - Incompatibility leading to possible precipitation when co-administered intravenously (EPITT no 18790)
Estonian: Tsiprofloksatsiin; meropeneem - sobimatus, mis samaaegsel intravenoossel manustamisel võib põhjustada sadet (EPITT nr 18 790)
English: Prednisolone; prednisone - Induced scleroderma renal crisis (EPITT no 18888)
Estonian: Prednisoloon; prednisoon - steroid-indutseeritud süsteemse skleroosi renaalne kriis (EPITT nr 18888)
English: Undesirable effects - table of ADRs - both for Chronic renal failure patients and for Cancer patients:
Estonian: Kõrvaltoimed - kõrvaltoimete tabel - nii kroonilise neerupuudulikkusega patsiendid kui ka vähipatsiendid
English: Section Possible side effects
Estonian: Lõik „Võimalikud kõrvaltoimed“
English: Stop using <product name> if you develop these symptoms and contact your doctor or seek medical attention immediately.
Estonian: Nende sümptomite tekkimisel lõpetage <ravimi nimetus omastavas käändes> kasutamine ja võtke kohe ühendust oma arstiga või pöörduge meditsiiniasutusse.